Literature DB >> 27238627

Introduction: Determinants of polycystic ovary syndrome.

Ricardo Azziz1.   

Abstract

The polycystic ovary syndrome (PCOS) is recognized as one of the most common endocrine abnormalities of humans, with global prevalences so far generally 5%-15%. Overall, the disorder appears to be an ancient complex genetic trait, perhaps dating at least 50,000 years ago. The phenotype of PCOS can be subdivided into four different types. Phenotype A and B (hyperandrogenism + ovulatory dysfunction, with [A] and without [B] polycystic ovarian morphology [PCOM], respectively) can be considered to represent the "classic" form of the disorder. Phenotype C is the so-called "ovulatory" PCOS (hyperandrogenism + PCOM only). And phenotype D is often referred to as "nonhyperandrogenic" PCOS (ovulatory dysfunction + PCOM only). The different phenotypes vary in the degree to which they are associated with an increased risk for metabolic dysfunction and reproductive complications. There are a number of determinants of the epidemiology (prevalence) and presentation (phenotype) of PCOS, including environmental (e.g., socioeconomic, geographic, toxicologic, life-style, and dietary) and genetic (e.g., gene variants, epigenetic, and race/ethnicity) factors. Finally a better understanding of the evolutionary determinants of PCOS has the potential for providing additional insight into those factors determining the etiology, prevalence, and persistence of a disorder that appears to be, superficially at least, an evolutionary paradox.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PCOS; epigenetics; evolution; genetics; genotype; phenotype; polycystic ovary syndrome; socioeconomics; toxicological

Mesh:

Year:  2016        PMID: 27238627     DOI: 10.1016/j.fertnstert.2016.05.009

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  28 in total

1.  miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.

Authors:  Jan M McAllister; Angela X Han; Bhavi P Modi; Maria E Teves; Grace R Mavodza; Zachary L Anderson; Tsaiwei Shen; Lane K Christenson; Kellie J Archer; Jerome F Strauss
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

Review 2.  Pathology of hyperandrogenemia in the oocyte of polycystic ovary syndrome.

Authors:  Neil R Chappell; William E Gibbons; Chellakkan S Blesson
Journal:  Steroids       Date:  2022-02-18       Impact factor: 2.668

3.  Hyperandrogenemia alters mitochondrial structure and function in the oocytes of obese mouse with polycystic ovary syndrome.

Authors:  Neil R Chappell; Beth Zhou; Pardis Hosseinzadeh; Amy Schutt; William E Gibbons; Chellakkan S Blesson
Journal:  F S Sci       Date:  2020-12-10

4.  The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity.

Authors:  D Abdulkhalikova; A Sustarsic; Eda Vrtačnik Bokal; N Jancar; M Jensterle; T Burnik Papler
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

5.  Current Situation and Demand for Continuing Medical Education (CME) for Obstetricians and Gynecologists.

Authors:  Hanbi Wang; Zhiyuan Zhang; Jie Chen; Han Dong; Ying Zou; Wei Wang; Qingmei Zheng; Ying Feng; Zhangyun Tan; Xiaoqin Zeng; Yinqing Zhao; Yanfang Wang; Aijun Sun
Journal:  J Multidiscip Healthc       Date:  2022-10-12

6.  Overexpression of Lnk in the Ovaries Is Involved in Insulin Resistance in Women With Polycystic Ovary Syndrome.

Authors:  Meihua Hao; Feng Yuan; Chenchen Jin; Zehong Zhou; Qi Cao; Ling Xu; Guanlei Wang; Hui Huang; Dongzi Yang; Meiqing Xie; Xiaomiao Zhao
Journal:  Endocrinology       Date:  2016-07-26       Impact factor: 4.736

7.  Polycystic Ovarian Syndrome Genetics and Epigenetics.

Authors:  Joshua C Combs; Micah J Hill; Alan H Decherney
Journal:  Clin Obstet Gynecol       Date:  2021-03-01       Impact factor: 1.966

8.  Small leucine-rich proteoglycans (SLRPs) in the endometrium of polycystic ovary syndrome women: a pilot study.

Authors:  Ricardo Santos Simões; José Maria Soares; Manuel J Simões; Helena B Nader; Maria Cândida P Baracat; Gustavo Arantes R Maciel; Paulo C Serafini; Ricardo Azziz; Edmund C Baracat
Journal:  J Ovarian Res       Date:  2017-08-08       Impact factor: 4.234

9.  Embryos from polycystic ovary syndrome patients with hyperandrogenemia reach morula stage faster than controls.

Authors:  Neil Ryan Chappell; Maya Barsky; Jaimin Shah; Mary Peavey; Liubin Yang; Haleh Sangi-Haghpeykar; William Gibbons; Chellakkan Selvanesan Blesson
Journal:  F S Rep       Date:  2020-09-02

10.  Response to ovulation induction treatments in women with polycystic ovary syndrome as a function of serum anti-Müllerian hormone levels.

Authors:  Stylianos Vagios; Caitlin R Sacha; Karissa C Hammer; Irene Dimitriadis; Kaitlyn E James; Charles L Bormann; Irene Souter
Journal:  J Assist Reprod Genet       Date:  2021-05-01       Impact factor: 3.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.